VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Escherichia coli rfaL mutant vaccine
Vaccine Information
  • Vaccine Name: Escherichia coli rfaL mutant vaccine
  • Target Pathogen: Escherichia coli
  • Target Disease: Hemorrhagic colitis
  • Vaccine Ontology ID: VO_0002839
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • rfaL gene engineering:
    • Type: Gene mutation
    • Description: This mutant is from Escherichia coli (Billips et al., 2009).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Bladder instillation
Host Response

Mouse Response

  • Persistence: An rfaL mutant is attenuated in mice (Billips et al., 2009).
  • Efficacy: An rfaL mutant induces significant protection in mice from challenge with wild type E. coli. Protection lasted more than 8 weeks (Billips et al., 2009).
  • Host IL-6 response
    • Description: NU14 ΔwaaL significantly enhanced mouse macrophage IL-6 secretion relative to wild-type NU14 4 hours after treatment. TNF-alpha reduced IL-6 expression of deletion mutants, but under these conditions IL-6 was expressed more than that expressed by macrophages infected with the wild type in the presence of TNF-alpha (Billips et al., 2009).
    • Detailed Gene Information: Click Here.
References
Billips et al., 2009: Billips BK, Yaggie RE, Cashy JP, Schaeffer AJ, Klumpp DJ. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. The Journal of infectious diseases. 2009; 200(2); 263-272. [PubMed: 19522648].